Should it matter where a new medicine was first discovered? John Stanford examines how global biotech partnerships can support American drug development, and why restricting them may have consequences for patients. #Biotech #Innovation #Biotechnology @johnbstanford @MedicineMa80739 @incub8coalition @SMMT_TX

$120 billion in China biotech deals. But how much has actually been paid? John Stanford explains why licensing headlines can overstate actual cash flows—and what that means for U.S. biotech policy. #ChinaBiotech #BiotechInvestment #biotech #innovation #shorts youtu.be/0gtjKQjiLkE?si=L9Pr… via @YouTube @MakingMedPod @MedicineMa80739 @johnbstanford @incub8coalition @FiercePharma @FierceBiotech @FDA @NIH

💊Why are so many new medicines unavailable in Japan? @johnbstanford examines Japan's drug lag, pricing policies, and delayed pharmaceutical launches with @MNakada and @mjgutbrod. 🎙️Watch the episode on YouTube @MakingMedicinePod @JNJInnovation @incub8coalition @IAmBiotech @MedicineMa80739 #biotech #innovation #sh... youtu.be/dnoWhgDdkPY?si=3qrX… via @YouTube

Could Drug Price Controls Reduce Biotech Investment? What happens to biotech R&D when drug pricing rules change? Eddie Pauline explains why he believes government price-setting policies could affect future investment in pharmaceutical innovation. #biotech #innovation #ohio #mfn @incub8coalition @johnbstanford @cardinalhealth @LifeSciVC @MakingMedPod @MedicineMa80739 youtube.com/shorts/R62A1Fnbd… via @YouTube

“And we’re behind.” Eddie Pauline discusses China’s expanding biotech investment and clinical trial capabilities, and the opportunity to strengthen U.S. biotechnology through research hubs like Ohio. youtu.be/1K9tZSpMVwI?si=N0xE… via @YouTube #biotech #innovation #shorts @johnbstanford @incub8coalition @OSUWexMed @ClevelandClinic @JobsOhio @MedicineMa80739

Ohio Has 10% of America’s Gene Therapies? Ohio isn't just competing for biotech investment. It's building a gene therapy ecosystem. Eddie Pauline discusses Nationwide Children's role in roughly 10% of FDA-approved gene therapies and why biotech companies are taking notice. #biotech #innovation #shorts @OSUWexMed @NCHUrology @cardinalhealth @USGAO @LifeSciVC @NationwideKids @ClevelandClinic @JobsOhio @FDA @johnbstanford @incub8coalition @NIH @MakingMedPod @MedicineMa80739 youtu.be/ulF3t9HuURU?si=-mbT… via @YouTube

🧬 Biotech isn't just Boston and San Francisco anymore. Ohio Life Sciences CEO Eddie Pauline joins @johnbstanford to discuss Ohio's biotech growth, gene therapy, investment, drug pricing, and competition with China. 🎙️ Watch the new Making Medicine episode! #Biotech #LifeSciences @incub8coalition @OSUWexMed @NCHUrology @cardinalhealth @USGAO @LifeSciVC @nationwidekids @ClevelandClinic @JobsOhio @FDA @MakingMedPod @MedicineMa80739 Ohio’s Biotech Boom: Gene Therapy, Investment & the Race with China youtu.be/RsTFS-GNI-8?si=W9HY… via @YouTube

Can AI Really Deliver 100 Years of Biotech Progress in 10? #biotech #inn... youtu.be/nYYle-5Ng8Q?si=muic… via @YouTube “100 years of biotech in the next 10 years.” It's a powerful prediction about AI. Thomas Kaiser does the math, and argues that fulfilling it would require roughly 450–550 new drugs per year. Transformative technology? Absolutely. But extraordinary claims still need numbers behind them. #AI #Biotech #DrugDiscovery @johnbstanford @incub8coalition @FDA @NIH @DCVCBio @DCVC @AvicennaAi @MedicineMa80739

“Good Ideas Are Cheap”: The Reality of AI Drug Discovery #shorts #biotec... youtu.be/ngcdVgkjBWI?si=cTD2… via @YouTube “Good ideas are cheap. Durable ideas are the hard part.” That's Thomas Kaiser's reality check for AI in drug discovery. AI can dramatically expand what scientists can explore. But generating more ideas isn't the same as producing more successful medicines. #AIDrugDiscovery #Biotech #AI @incub8coalition @johnbstanford @FDA @NIH @AvicennaAi @DCVCBio @DCVC @MedicineMa80739

11 Compounds. 2 Drug Candidates. Is This AI’s Biotech Breakthrough? #sho... youtu.be/_VJ5-XjV42A?si=UX2N… via @YouTube Full Episode out NOW! #AIDrugDiscovery #Biotech #DrugDiscovery @incub8coalition @johnbstanford @DCVCBio @DCVC @MedicineMa80739

$12 billion. That's roughly a quarter of the venture capital invested in life sciences in 2025, committed to a single biotech acquisition. John Stanford explains what the Novartis/Avidity story reveals about the extraordinary risk behind drug development. Watch the full episode on YouTube @MakingMedicinePod #Biotech #Pharma #DrugDevelopment #LifeSciences